UK Geographic Atrophy (GA) Market

ID: MRFR/HC/49909-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026
UK Geographic Atrophy GA Market Research Report By Age Group (Above 60 Years, Above 75 Years), By Diagnosis (Fundus Autofluorescence, Optical Coherence Tomography Angiography, Multifocal Electroretinography) andBy Therapeutic Agents Clinical Phase (Late-Stage, Phase II, Phase I, Pre-Clinical Stage, Discovery Candidates) - Growth & Industry Forecast 2025 To 2035
UK Geographic Atrophy (GA) Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.53%
2024 Market Size$ 1,739.48 Million
2025 Market Size$ 1,870.46 Million
2035 Market Size$ 3,865 Million
Key Players
Novartis
Regeneron Pharmaceuticals
Roche
Bayer
Alcon
Apellis Pharmaceuticals
Trends
  • Rising Prevalence of AMD
  • Advancements in Diagnostic Technologies
  • Regulatory Changes and Clinical Trials
Opportunities
  • Increasing Aging Population
  • Rising Healthcare Expenditure
  • Growing Awareness and Education
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Security, Access Control and Robotics, BY Age Group (USD Million)
      1. 4.1.1 Above 60 Years
      2. 4.1.2 Above 75 Years
    2. 4.2 Security, Access Control and Robotics, BY Diagnosis (USD Million)
      1. 4.2.1 Fundus Autofluorescence (FAF)
      2. 4.2.2 Optical Coherence Tomography Angiography (OCT-A)
      3. 4.2.3 Multifocal Electroretinography (MfERG)
    3. 4.3 Security, Access Control and Robotics, BY Therapeutic Agents Clinical Phase (USD Million)
      1. 4.3.1 Late-Stage (Phase III)
      2. 4.3.2 Phase II
      3. 4.3.3 Phase I
      4. 4.3.4 Pre-Clinical Stage & Discovery Candidates
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Regeneron Pharmaceuticals (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bayer (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Alcon (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Apellis Pharmaceuticals (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Santen Pharmaceutical (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Horizon Therapeutics (IE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY AGE GROUP
    3. 6.3 UK MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 UK MARKET ANALYSIS BY THERAPEUTIC AGENTS CLINICAL PHASE
    5. 6.5 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
    8. 6.8 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    10. 6.10 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
    11. 6.11 SECURITY, ACCESS CONTROL AND ROBOTICS, BY AGE GROUP, 2024 (% SHARE)
    12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY AGE GROUP, 2024 TO 2035 (USD Million)
    13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS, 2024 (% SHARE)
    14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2024 (% SHARE)
    16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY AGE GROUP, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
      3. 7.2.3 BY THERAPEUTIC AGENTS CLINICAL PHASE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Geographic Atrophy (GA) Market Segmentation

UK Geographic Atrophy (GA) Market By Age Group (USD Million, 2025-2035)

  • Above 60 Years
  • Above 75 Years

UK Geographic Atrophy (GA) Market By Diagnosis (USD Million, 2025-2035)

  • Fundus Autofluorescence (FAF)
  • Optical Coherence Tomography Angiography (OCT-A)
  • Multifocal Electroretinography (MfERG)

UK Geographic Atrophy (GA) Market By Therapeutic Agents Clinical Phase (USD Million, 2025-2035)

  • Late-Stage (Phase III)
  • Phase II
  • Phase I
  • Pre-Clinical Stage & Discovery Candidates

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.